Abstract
Objective: To detect mutations of trypsinogen gene (PRSS1) in patients with autoimmune pancreatitis (AIP) and to determine the underlying pathogenesis.
Methods: DNA sequencing was used to detect full-length of PRSS1, cystic fibrosis transmembrane conductance regulator (CFTR), and pancreatic secretory trypsin inhibitor (SPINK1) genes mutations in an AIP family and a sporadic case and 520 normal controls. Furthermore, a mutant-expressing system was constructed for functional confirmation.
Results: For the first time, we report a deletion mutation at exon 2 of PRSS1 gene (IVS 2 +56_60 del CCCAG) which encoded a truncated PRSS1 protein without trypsinogen activation peptide (TAP). Vitro functional study suggested the identified mutation would result in loss of PRSS1 activity. Mutant trypsinogen activated at a faster rate than wild-type trypsinogen in the autoactivation experiment. Histopathologic examination revealed the ratio of IgG4/IgG-positive plasma cells exceeded 0.455 in pancreas, and the patients responded to glucocorticoids.
Conclusion: PRSS1: IVS 2 +56_60 del CCCAG is a noval mutant which may contribute to AIP pathogenesis.
Keywords: Autoimmune pancreatitis, IVS 2 +56_60 del CCCAG mutation, molecular mechanism, PRSS1 gene.
Current Molecular Medicine
Title:Identification of a Novel Frame-Shift Mutation in PRSS1 Gene in Han Patients with Autoimmune Pancreatitis
Volume: 14 Issue: 3
Author(s): F. Gao, Y. Li, C. Wang, Z. Zhuang, Q.C. Liu, J. Chen, G. Hong and Z. Xu
Affiliation:
Keywords: Autoimmune pancreatitis, IVS 2 +56_60 del CCCAG mutation, molecular mechanism, PRSS1 gene.
Abstract: Objective: To detect mutations of trypsinogen gene (PRSS1) in patients with autoimmune pancreatitis (AIP) and to determine the underlying pathogenesis.
Methods: DNA sequencing was used to detect full-length of PRSS1, cystic fibrosis transmembrane conductance regulator (CFTR), and pancreatic secretory trypsin inhibitor (SPINK1) genes mutations in an AIP family and a sporadic case and 520 normal controls. Furthermore, a mutant-expressing system was constructed for functional confirmation.
Results: For the first time, we report a deletion mutation at exon 2 of PRSS1 gene (IVS 2 +56_60 del CCCAG) which encoded a truncated PRSS1 protein without trypsinogen activation peptide (TAP). Vitro functional study suggested the identified mutation would result in loss of PRSS1 activity. Mutant trypsinogen activated at a faster rate than wild-type trypsinogen in the autoactivation experiment. Histopathologic examination revealed the ratio of IgG4/IgG-positive plasma cells exceeded 0.455 in pancreas, and the patients responded to glucocorticoids.
Conclusion: PRSS1: IVS 2 +56_60 del CCCAG is a noval mutant which may contribute to AIP pathogenesis.
Export Options
About this article
Cite this article as:
Gao F., Li Y., Wang C., Zhuang Z., Liu Q.C., Chen J., Hong G. and Xu Z., Identification of a Novel Frame-Shift Mutation in PRSS1 Gene in Han Patients with Autoimmune Pancreatitis, Current Molecular Medicine 2014; 14 (3) . https://dx.doi.org/10.2174/1566524013666131118114432
DOI https://dx.doi.org/10.2174/1566524013666131118114432 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Detection of Damaging nsSNPs on Human Caspase-Cascades Related to Apoptotic Signalling Pathway
Protein & Peptide Letters Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry Potential of Liposomes for Enhancement of Oral Drug Absorption
Current Drug Delivery The Synthesis, Anticancer Activity, Structure-Activity Relationships and Molecular Modelling Studies of Novel Isoindole-1,3(2H)-dione Compounds Containing Different Functional Groups
Anti-Cancer Agents in Medicinal Chemistry Intestinal Targeting of Drugs: Rational Design Approaches and Challenges
Current Topics in Medicinal Chemistry Human Exfoliated Deciduous Teeth Stem Cells: Features and Therapeutic Effects on Neurogenerative and Hepatobiliary-pancreatic Diseases
Current Stem Cell Research & Therapy Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography
Reviews on Recent Clinical Trials Complex Obesity
Current Pediatric Reviews Cholestasis During Pregnancy: Aetiopathogenesis, Foetal-Maternal Repercussions and Pharmacological Treatments
Current Women`s Health Reviews Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Bile Acid Derivatives as Ligands of the Farnesoid X Receptor: Molecular Determinants for Bile Acid Binding and Receptor Modulation
Current Topics in Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Emerging Therapeutic Potential of Whey Proteins and Peptides
Current Pharmaceutical Design Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry